Meeting report: Using stem cells for biological and therapeutics discovery in mental illness, April 2012

Stem Cells Translational Medicine

Volumn 2, Issue 3, 2013, Pages 217-222

  Panchision, David M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Direct cell conversion; Experimental models; Genomics; Induced pluripotent stem cells; Neural differentiation; Neuron; Reprogramming

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CELL SURFACE MARKER; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; LITHIUM;

ARTICLE; AUTISM; BIPOLAR DISORDER; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DOPAMINERGIC NERVE CELL; DRUG RESPONSE; FRAGILE X SYNDROME; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOCYTOCHEMISTRY; MENTAL DISEASE; MOTONEURON; NERVE CELL DIFFERENTIATION; NONHUMAN; NUCLEAR REPROGRAMMING; PATHOPHYSIOLOGY; PATIENT SELECTION; PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; POLYMERASE CHAIN REACTION; RETT SYNDROME; SCHIZOPHRENIA;

EID: 84875115909     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0149     Document Type: Article

References (26)

1. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012;483:531-533.
2. Schulze TG, Akula N, Breuer R et al. Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. World J Biol Psychiatry 2012 (in press).
3. Anney R, Klei L, Pinto D et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum Mol Genet 2012;21:4781-4792.
4. Urbach A, Bar-Nur O, Daley GQ et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010;6:407-411.
5. Sheridan SD, Theriault KM, Reis SA et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011;6:e26203.
6. Bar-Nur O, Caspi I, Benvenisty N. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 2012;4:180-183.
7. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-539.
8. Cheung AY, Horvath LM, Carrel L et al. Xchromosome inactivation in Rett syndrome human induced pluripotent stem cells. Front Psychiatry 2012;3:24.
9. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci USA 2011;108:14169-14174.
10. Ananiev G, Williams EC, Li H et al. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS One 2011;6:e25255.
11. Farra N, Zhang WB, Pasceri P et al. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 2012;17:1261-1271.
12. Abyzov A, Mariani J, Palejev D et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 2012;492:438-442.
13. Cheng L, Hansen NF, Zhao L et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012;10:337-344.
14. Lujan E, Chanda S, Ahlenius H et al. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci USA 2012;109:2527-2532.
15. Muller FJ, Laurent LC, Kostka D et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008;455:401-405.
16. Muller FJ, Schuldt BM, Williams R et al. A bioinformatic assay for pluripotency in human cells. Nat Methods 2011;8:315-317.
17. Mekhoubad S, Bock C, de Boer AS et al. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012;10:595-609.
18. Goulburn AL, Alden D, Davis RP et al. A targeted NKX2.1 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. STEM CELLS 2011;29: 462-473.
19. Pasca SP, Portmann T, Voineagu I et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17:1657-1662.
20. Mariani J, Simonini MV, Palejev D et al. Modeling human cortical development in vitro using induced pluripotent stem cells. Proc Natl Acad Sci USA 2012;109:12770-12775.
21. Chiang CH, Su Y, Wen Z et al. Integrationfree induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry 2011;16:358-360.
22. Lin M, Pedrosa E, Shah A et al. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 2011;6:e23356.
23. Zhao WN, Cheng C, Theriault KM et al. A high-throughput screen for Wnt/beta-catenin signaling pathway modulators in human iPSCderived neural progenitors. J Biomol Screen 2012;17:1252-1263.
24. Hempel CM, Sivula M, Levenson JM et al. A system for performing high throughput assays of synaptic function. PLoS One 2011;6: e25999.
25. Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-406.
26. Lowenthal J, Lipnick S, Rao M et al. Specimen collection for induced pluripotent stem cell research: Harmonizing the approach to informed consent. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:409-421.